Bernd Hentsch

Direktor/Vorstandsmitglied bei G2M Cancer Drugs AG

64 Jahre

Health Technology

Commercial Services

Retail Trade

Aktive Positionen von Bernd Hentsch

Unternehmen	Position	Beginn	Ende
G2M Cancer Drugs AG G2M Cancer Drugs AG Miscellaneous Commercial ServicesCommercial Services Part of Valerio Therapeutics SA, G2M Cancer Drugs AG is a German company that researches new anti-cancer therapeutics and develops selected late-stage products. The company is based in Frankfurt am Main, Germany. G2M Cancer Drugs was acquired by Topotarget A/S on March 01, 2005.	Direktor/Vorstandsmitglied	01.01.2001	-

Unternehmen	Position	Beginn	Ende
4SC AG	Corporate Officer/Principal	11.05.2010	-
TopoTarget UK Ltd. TopoTarget UK Ltd. Drugstore ChainsRetail Trade TopoTarget UK Ltd. engages in the discovery and development of drugs and therapies to treat cancer. It develops anti-cancer drugs for molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company was founded in 2002 and is headquartered in Oxford, the United Kingdom.	Corporate Officer/Principal	-	-

Julius-Maximilians-Universität Würzburg

Doctorate Degree

International

Deutschland	4
Vereinigtes Königreich	2

Operativ

Corporate Officer/Principal	2
Director/Board Member	1
Doctorate Degree	1

Sektoral

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	1
4SC AG	Health Technology

Private Unternehmen	2
G2M Cancer Drugs AG G2M Cancer Drugs AG Miscellaneous Commercial ServicesCommercial Services Part of Valerio Therapeutics SA, G2M Cancer Drugs AG is a German company that researches new anti-cancer therapeutics and develops selected late-stage products. The company is based in Frankfurt am Main, Germany. G2M Cancer Drugs was acquired by Topotarget A/S on March 01, 2005.	Commercial Services
TopoTarget UK Ltd. TopoTarget UK Ltd. Drugstore ChainsRetail Trade TopoTarget UK Ltd. engages in the discovery and development of drugs and therapies to treat cancer. It develops anti-cancer drugs for molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company was founded in 2002 and is headquartered in Oxford, the United Kingdom.	Retail Trade